Here's Why Intercept Pharma (ICPT) Stock Is Gaining Today - TheStreet.com

TheStreet.com

Here's Why Intercept Pharma (ICPT) Stock Is Gaining Today TheStreet.com Intercept Pharma (ICPT) stock is higher in mid-afternoon trading after the company's treatment for chronic liver disease received accelerated FDA approval. Rachel Graf. Follow. May 31, 2016 1:36 PM EDT. Get TheStreet Quant Ratings' exclusive 5-page ... Intercept Pharma's new liver disease drug comes with hefty price tag: $70000 a yearMarketWatch Ocaliva Approved for Rare Liver DiseasePhilly.com Intercept Pharmaceuticals (ICPT) PT Comes Down to $239 at Wedbush Following OCALIVA ApprovalStreetInsider.com Examiner.com -Benzinga -P&T Community -Pharmacy Times all 23 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFdXilzQplBHElI0akeHa_8wfUZ7A&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779123871458&ei=GPRNV5juLMGb3QHIqJCwCw&url=https://www.thestreet.com/story/13590613/1/here-s-why-intercept-pharma-icpt-stock-is-gaining-today.html
via IFTTT